Matarin Capital Management’s Lifecore Biomedical LFCR Stock Holding History

Matarin Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-15,736	Closed	-$186K	–	239
2015 Q4	$186K	Buy	15,736 +3,478	+28%	+$42.7K	0.03%	218
2015 Q3	$143K	Sell	12,258 -17,989	-59%	-$238K	0.03%	208
2015 Q2	$436K	Buy	30,247 +2,535	+9%	+$36.6K	0.13%	166
2015 Q1	$387K	Buy	27,712 +4,530	+20%	+$62.6K	0.12%	162
2014 Q4	$320K	Hold	23,182	–	–	0.14%	141
2014 Q3	$284K	Buy	+23,182	New	+$289K	0.13%	157

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

NIMC

NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Matarin Capital Management's LFCR Position: Q1 2016 in Review

Matarin Capital Management sold out of Lifecore Biomedical (LFCR) in Q1 2016, closing a stake of 15,736 shares — an estimated $186K sold.

Matarin Capital Management first reported a position in LFCR in Q3 2014 and held it in 6 quarters. The position peaked at $436K in Q2 2015. 96 funds tracked by Wall St. Rank hold LFCR as of Q1 2016.

Matarin Capital Management reported no remaining Lifecore Biomedical position as of Q1 2016 after selling out during the quarter.
Matarin Capital Management sold 15,736 Lifecore Biomedical shares in Q1 2016, an estimated $186K.
Matarin Capital Management first reported a position in Lifecore Biomedical in Q3 2014 and held it in 6 quarters.
Matarin Capital Management's Lifecore Biomedical position peaked at $436K in Q2 2015.
96 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2016.

Based on Matarin Capital Management's 13F filing for Q1 2016, filed 10 May 2016.